Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Iraq

Iraq

The Other Vaccines market in Iraq is expected to experience significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$57.15m.
This upward trend is expected to continue with an annual growth rate (CAGR 2024-2029) of 10.58%, resulting in a market volume of US$94.51m by 2029.
When compared to other countries around Worldwide, United States is set to generate the highest revenue in this market.
In 2024 alone, United States is projected to generate an impressive US$24,730.00m in revenue.
Iraq is experiencing a growing demand for other vaccines, driven by increased awareness of the importance of immunization.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Iraq has been showing steady growth in recent years.

Customer preferences: Iraq has a young population with a high birth rate, which has led to an increase in demand for vaccines. The government has been actively promoting vaccination programs, which has resulted in a growing awareness of the importance of preventive healthcare among the population.

Trends in the market: The Other Vaccines market in Iraq is expected to grow in the coming years due to the introduction of new vaccines and the expansion of vaccination programs. The market is dominated by multinational companies, but there is also a significant presence of local players. The demand for vaccines is expected to increase as the population continues to grow, and as the government continues to prioritize healthcare spending.

Local special circumstances: Iraq has been facing numerous challenges in recent years, including political instability and conflict. However, despite these challenges, the healthcare sector has remained resilient and has continued to grow. The government has been investing in healthcare infrastructure and has been working to improve access to healthcare services.

Underlying macroeconomic factors: The Iraqi economy has been recovering in recent years, with GDP growth expected to continue in the coming years. The government has been implementing economic reforms and has been working to attract foreign investment. The healthcare sector is expected to benefit from these reforms, as increased investment and economic growth will lead to an increase in healthcare spending. Additionally, the government has been working to diversify the economy, which will reduce the country's reliance on oil exports and will lead to increased economic stability.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.